| Acquirer | Target | Price |
|---|---|---|
| Gilead Sciences Inc. | Nimbus Apollo program | $400 million |
| Janssen Biotech Inc. | License for niraparib | $315 million |
| Allergan plc | Exclusive rights to CNS treatments | $125 million |
| Curahealth LLC | 12 LTAC hospitals | $27.5 million |
| Fairview Health Services | Ucare | Merger |
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
